<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940235</url>
  </required_header>
  <id_info>
    <org_study_id>IEO 997</org_study_id>
    <nct_id>NCT03940235</nct_id>
  </id_info>
  <brief_title>Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis</brief_title>
  <acronym>RADIOSA</acronym>
  <official_title>Radioablation +/- Hormonotherapy for Prostate Cancer Oligorecurrences (RADIOSA Trial): Potential of Imaging and Biology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Institute of Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized phase II clinical trial (RADIOSA trial: Radioablation with or without Androgen
      DeprIvation therapy in metachronous prostate cancer OligometaStAsis).

      The aim is to compare time to progression between the two study arms: SBRT only or SBRT and
      hormonotherapy (ADT). The primary objective is to compare the progression-free survival (PFS)
      defined as the absence of new metastatic lesions (local, regional or distant) between the two
      arms. The secondary endpoints include the comparison of overall survival (OS), biochemical
      progression-free survival (BPFS), ADT-free survival, local control, treatment-induced acute
      and late toxicity, time to castration-resistant disease and QoL between the two arms; the
      development of a dedicated biobanking (collection of plasma and serum) for further biological
      investigation of predictive/diagnostic factors for personalized treatment; the preliminary
      evaluation of prognostic biomarkers; the correlation between imaging-derived parameters and
      treatment outcome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up 3 months from the end of the treatment up to radiological progression within 3 years</time_frame>
    <description>Defined as the absence of new metastatic lesions (local, regional or distant) between the two arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up the end of SBRT until death for cancer or other causes up to 3 years</time_frame>
    <description>From the end of RT treatment to the time of clinical progression or mortality from specific disease cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical progression-free survival (BPFS)</measure>
    <time_frame>up 3 months from the end of the treatment up to 3 years</time_frame>
    <description>Biochemical progression is defined according to the EAU guidelines [18], namely a rising PSA level &gt;0.2 ng/ml following radical prostatectomy and &gt;2 ng/ml above the nadir after radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of patients who experienced acute and late toxicity</measure>
    <time_frame>Up to 1 months after treatment completion and then up to 3 years</time_frame>
    <description>Toxicity will be assessed according to the Common Toxicity Criteria for adverse events (CTCAE) toxicity criteria v4.3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Oligometastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Stereotactic body Radiotherapy (SBRT) only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARM 1: salvage SBRT for lymph nodes and/or bone metastases. All the radiologically documented lesions will be treated simultaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic body Radiotherapy (SBRT) and hormonotherapy (ADT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARM 2: salvage SBRT (as described for ARM 1) + 6-month ADT (luteinizing hormone-releasing hormone (LHRH) agonist or antagonist). ADT should start within one week before the start of SBRT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androgen deprivation therapy (ADT)</intervention_name>
    <description>SBRT + ADT</description>
    <arm_group_label>Stereotactic body Radiotherapy (SBRT) and hormonotherapy (ADT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>SBRT to all radiological documented lesions (bone or lymphnodes)</description>
    <arm_group_label>Stereotactic body Radiotherapy (SBRT) and hormonotherapy (ADT)</arm_group_label>
    <arm_group_label>Stereotactic body Radiotherapy (SBRT) only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven initial diagnosis of adenocarcinoma of the prostate;

          -  Biochemical relapse of PCa following radical local prostate treatment (radical
             prostatectomy, primary radiotherapy or radical prostatectomy +/- prostate bed
             adjuvant/salvage radiotherapy) +/- ADT according to the European Association of
             Urology (EAU) guidelines 2016 [18] or after any salvage therapy if biochemical
             progression is diagnosed in the context of castration sensitive PCa;

          -  Nodal relapse in the pelvis, extra-regional nodal relapse (M1a), bone metastases (M1b)
             on Ch-PET/CT or WBMRI with a maximum of 3 lesions;

          -  Serum testosterone level &gt;50 ng/dl at the time of randomization (castration sensitive
             PCa)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1;

          -  Age â‰¥18 years;

          -  Written informed consent signed

        Exclusion criteria

          -  Serious concomitant comorbidities or contraindication to SBRT and/or ADT;

          -  Previous invasive cancer (within 3 years before the prostate cancer diagnosis) apart
             from non-melanoma skin malignancies;

          -  No ability to complete questionnaires about QoL;

          -  Presence of mental diseases that cannot ensure valid informed consent;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara A Jereczek-Fossa, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Istituto Europeo di Oncologia IRCCS Milan, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara A Jereczek-Fossa, Prof</last_name>
    <phone>+39 0257489037</phone>
    <email>barbara.jereczek@ieo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giulia marvaso, MD</last_name>
    <phone>+39 0294372696</phone>
    <email>giuliamarvaso@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia IRCCS</name>
      <address>
        <city>Milan</city>
        <state>MI - Milano</state>
        <zip>20135</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara A Jereczek-Fossa, Prof</last_name>
      <phone>+39 0257489037</phone>
      <email>barbara.jereczek@ieo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

